Introduction
It may be argued that the most reliable way of identifying the side-effects pattern associated with a new drug substance is to administer that drug in isolation to patients suffering from the disease, or group of diseases for which it has been developed. In this way, effects possibly attributable to the drug can be discerned since they will not be masked or modified by concomitantly administered therapy.
It is recognized that this is a basically unrealistic situation, since the majority of individuals receiving a new drug for a chronic disorder of some body system will often already be receiving one or several other drugs for this, or unrelated conditions.
The practical approach therefore lies somewhere between these two extremes. It accepts that some information on those effects solely related to the new drug is clearly desirable, particularly in the early stages of investigation, but attaches perhaps even greater importance to the toxicological patterns observed in routine clinical practice, when the drug is being used alongside others.
Both of the above factors were taken into consideration in the development of the clinical research programme for fenclofenac (Flenac).
Methods
The central feature of this research programme has been the implementation of our open multicentre study, whose several functions have included a means of studying side-effects distribution and tolerance over prolonged periods of time.
The study was initiated in one centre in 1974, and since that time has been progressively extended. It now comprises 17 centres which together have contributed 412 patients to the study. The majority of patients have been treated with doses ranging from 600 to 1800mg daily (Fig 1) . In the early stages patients requiring any additional therapy, either for their rheumatological condition or for a co-existing, non-rheumatological condition were excluded from the study, but gradually, as the initial centres involved became more familiar with the drug and its behaviour, patients already established on medication which would not routinely require to be discontinued if fenclofenac were to be added, were permitted to enter it. The majority of the study to date, therefore, has been conducted under realistic clinical conditions. Full details of the design of the open study have been described elsewhere (Goldberg et al. 1975 ). The features pertinent to the present paper have been:
(1) Intensive monitoring of a wide range of haematological and biochemical parameters at baseline and at regular intervals thereafter.
(2) Full renal function monitoring including urine concentration tests in a selected group of patients. Fenclofjnac mately one-third of the patients and routine checks by the supervising physicians in the remainder.
(4) Regular recording of all side-effects elicited in response to the standard question: 'Have the tablets upset you in any way?' (5) Meticulous recording of any medication taken in addition to fenclofenac during the course of the study.
Direct questioning regarding side-effects is subject to criticism on the grounds that it may produce a spuriously high incidence of unwanted effects. After due consideration of alternative techniques, however, such an approach was considered more acceptable as an early warning system than reliance solely upon spontaneously volunteered effects.
Results
The majority of side-effects reported to date have been of a minor character. This is indicated by the fact that the total of 636 unwanted effects were reported by 229 out of 412 patients (56%). A number of patients reported two or more sideeffects and, indeed, 11 different effects were registered by one patient! It is significant that 44% of patients in this study did niot report an adverse effect even on direct questioning.
Out of the total patient population 79 (19.2%) were withdrawn from therapy because of intolerance. However, 13 patients subsequently restarted fenclofenac therapy without further evidence of intolerance, and therefore only 66 patients (16.0 %) were totally unable to take fenclofenac.
Gastrointestinal, central nervous system, and dermatological effects comprised 700% of all reports and a breakdown of these and other effects which occurred with much reduced frequency are illustrated in Table 1 . Gastrointestinal side-effects mainly consisted of mild dyspepsia although 2 patients did discontinue fenclofenac therapy because of epigastric pain.
A further 13 patients ceased therapy because of other gastrointestinal effects which included nausea and diarrhoea. One patient suffered a hmematemesis but was subsequently found to have a past history strongly suggestive of peptic ulcer.
Effects attributable to the central nervous system ranged from headache and dizziness to a migraine-like syndrome, but withdrawal of therapy was necessary in only 11 cases.
Dermatological side-effects comprised 14.3 % of all reports. A variety of reactions were reported, the most frequLent of these being a diffuse maculopapular rash occasionally associated with pruritus. This rash, which was generally mild in character, tended to occur within the first four weeks of therapy, and usually cleared rapidly within 48 hours of withdrawal of therapy. There has been no evidence to date to suggest that the rash, when it occurs, is in any way associated with vasculitic changes. Initially, 34 patients were withdrawn from therapy as a result of rash, but 6 of these have now been successfully iestarted, without a recurrence. The current withdrawal rate of this effect is thus 6.8 %.
More infrequently, reports have been associated with ophthalmological, cardiovascular and genitourinary effects. Routine initial and followup ophthalmological assessments have been carried out in a large group of patients throughout the course of the study, with minimal findings. In a number of cases reports of 'gritty eyes' have been identified as cases of keratoconjunctivitis sicca. One female patient (aged 63), for whom no pre-treatment assessment was available, had very early 'blue dot' lenticular opacities of the familial type. The familial origin in this case is reinforced by the fact that this patient's elderly brother, who had never received fenclofenac, had similar opacities. Another patient developed macular cedema during the course of fenclofenac therapy which completely resolved when the drug was withdrawn. In a further case, macular degeneration was noted at the first examination following institution of therapy, and fenclofenac was withdrawn as a precautionary measure.
Swelling of the legs was reported on seven occasions. However, of the 4 patients withdrawn from therapy because of cardiovascular effects, none experienced significant swelling of the legs and these patients were withdrawn from the trial because of chest pain, postural hypotension (this patient was also receiving methyldopa four times daily), non-postural hypotension and anemia respectively. In this last patient the anemia was corrected and fenclofenac reinstituted without further untoward effect. A nephrotic syndrome occurred in one patient taking 750-1500 mg fenclofenac daily for six months; this patient was withdrawn from therapy and has since made a complete recovery which has been maintained for nearly one yeat after the appearance of the original nephrotic syndrome.
During the course of the trial, abnormalities in laboratory parameters resulted in withdrawal of 10 patients; 4 with raised tiansaminases, 4 with raised ureas, and one with a lowered platelet count. A further patient who developed a pancytopenia after almost a year of therapy was subsequently diagnosed as suffering from an immunoblastic sarcoma.
A large number of side-effects were classified as 'miscellaneous'. These included all manner of subjective effects, e.g. 'feeling under the weather', lack of libido, and earache. The generally trivial nature of these complaints is reinforced by the fact that only 2 patients were withdrawn from this group.
The number and percentage of patients withdrawn as a result of side-effects in each of the categories described above, are illustrated in Table 2 .
Discussion
Unwanted effects associated with therapy with non-steroidal anti-inflammatory agents are frequently related to the gastrointestinal tract, and range from mild dyspepsia to frank ulceration and hemorrhage. The incidence of these effects varies with the particular therapy employed and the dosage used.
Although animal studies may predict a low level of gastrointestinal toxicity in man (Atkinson et al., p 1; Rainsford, p 4), the final evaluation must be made in the clinic. The present study suggests that fenclofenac is associated with a low level of Although the appearance of a rash was the most frequent single cause of withdrawal of fenclofenac therapy, it was generally mild in character, and it has so far proved possible to reintroduce the drug without a recurrence in 6 out of 7 patients in whom this has been attempted. It has been observed in some cases that previous sensitivity to penicillin or aspirin may have predisposed patients to a rash on subsequent fenclofenac therapy and studies are in progress to investigate this further.
In general, no correlation has been shown between either side-effect pattern or the severity of the effect and dosage. When they have occurred, side-effects have been most frequent in the first four weeks of therapy.
Conclusions
Within the framework of a study approximating closely to the conditions of routine clinical practice, fenclofenac has been shown to be generally well tolerated in a significantly large group of patients, who have been monitored for prolonged periods. 
